GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment...

Related Keywords

Brisbane ,Queensland ,Australia ,Corey Davis ,David Castaneda ,Jeffrey Miller ,Michael Breen ,Prnewswire Gt Biopharma Inc ,Esmo Io Congress ,Source Gt Biopharma Inc ,Exchange Commission ,Development Rd Expenses ,Oncology Esmo Io Congress ,European Society For Medical Oncology Immuno ,University Of Minnesota ,Gt Biopharma Inc ,Company Tri ,Executive Chairman ,Interim Chief Executive ,Anticancer Therapies ,Chief Scientific Officer ,European Society ,Medical Oncology Immuno ,Tri Specific Killer Engager ,Year End ,Relations Contacts ,Gt Biopharma ,Nc ,